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Abstract
Myeloma facilitates destruction of bone and marrow. Since physical activity encourages 
musculoskeletal preservation we evaluated whether low-intensity vibrations (LIV), a component of 
mechanical signaling, could protect bone and marrow during myeloma progression. 
Immunocompromised-mice (n=25) were injected with human-myeloma cells, while 8 (AC) were 
saline-injected. Myeloma-injected mice (LIV; n=13) were subjected to daily-mechanical loading 
(15min/d; 0.3g @ 90Hz) while 12 (MM) were sham-handled. At 8w, femurs had 85% less 
trabecular bone volume (BV) fraction in MM versus AC, yet only a 21% decrease in LIV as 
compared to as compared to AC, reflecting a 76% increase versus MM. Cortical BV was 21% and 
15% lower in MM and LIV, respectively, than AC; LIV showing 30% improvement over MM. 
Similar outcomes were observed in the axial skeleton, showing a 35% loss in MM with a 27% 
improved retention of bone in L5 of LIV-treated mice as compared to MM. Transcortical-
perforations in the femur from myeloma-induced osteolysis were 9× higher in MM versus AC, 
reduced by 57% in LIV. Serum-TRACP5b, 61% greater in MM versus AC, rose by 33% in LIV 
compared to AC, a 45% reduction in activity when compared to MM. Histomorphometric analyses 
of trabecular bone demonstrated a 70% elevation in eroded surfaces of MM versus AC, while 
measures in LIV were 58% below those in MM. 72% of marrow in the femur of MM mice 
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contained tumor, contrasted by a 31% lower burden in LIV. MM mice (42%) presented advanced-
stage necrosis of marrow in the tibia while present in just 8% of LIV. Myeloma infiltration 
inversely correlated to measures of bone quality, while LIV slowed systemic myeloma-associated 
decline in bone quality and inhibited tumor progression through the hindlimbs.
1. Introduction
In the United States, there is a 0.7% lifetime risk of acquiring multiple myeloma, a cancer 
that forms from plasma cells and accumulates within the bone marrow, thus crowding out 
healthy blood cells (1, 2). Myeloma is the second most prevalent hematologic malignancy 
(3, 4), representing approximately 15% of all hematologic cancers (5), with 27 000 new U.S. 
cases projected to be diagnosed this year (1). Recently developed therapeutics have 
increased 5-year survival to 44%, yet over 11 000 patients still die of this disease each year 
in the U.S. Bone resorption is one of the defining comorbidities of myeloma, compromising 
skeletal quality and increasing fracture susceptibility in those with the disease (6, 7). Spread 
of malignant plasma cells through the bone marrow (BM) space also disrupts resident 
hematopoietic progenitors and weakens the immune response (8–10), and, in aggregate, 
consequences of BM crowding by myeloma contributes to decreased quality-of-life despite 
advances in treatment.
Pathologically, myeloma is characterized by a marked increase in plasma cell density within 
the BM (11–13), with tumor cell invasion disrupting the tightly orchestrated mechanisms 
that control bone remodeling while simultaneously creating an environment conducive to 
osteolytic lesions (4, 14). Further, the transformation of the BM into a tumor supportive 
niche leaves a less viable milieu for the mesenchymal stem cell population (MSC) that are 
critical for tissue regeneration, and hematopoietic stem cells (HSC) central to hematopoiesis 
and myelopoiesis (11, 15).
Cancer progression and the array of treatment strategies employed to manage the disease 
often result in a significant challenge to the skeleton (16–19). The long-term, catabolic 
impact of chemotherapy, irradiation, and immunosuppressive therapies on bone endpoints 
contribute heavily to osteopenia (20), especially for the very young (18, 21), frail elderly 
(22), and immunosuppressed (23). Routine treatment strategies, from high-dose 
chemotherapy to fractionated radiotherapies (24, 25), are aimed at slowing tumor expansion, 
but each approach is limited by adverse effects. For example, while irradiation is effective in 
combating tumor burden (24), it degrades the bone matrix (20) and damages the spectra of 
cellular constituents which govern bone remodeling (26). Chemotherapy diminishes tumor 
burden but, amongst other side effects, can be associated with renal toxicity and 
pancytopenia (25, 27). Extensive radiation and/or chemotherapy may necessitate BM 
transplantation, increasing likelihood of secondary side effects (i.e., graft-vs.-host disease, 
acute myelodysplastic leukemia, or myelodysplastic syndrome) (28, 29). Glucocorticoids 
(e.g. Dexamethasone) are efficacious in diminishing tumor burden, primarily as a function of 
dosing, yet, high-dose and/or chronic use are heavily associated with toxicity and result in 
osteoporotic bone (30, 31) by inducing apoptosis in osteoblasts and osteocytes (32). 
Immunosuppressive agents (e.g., corticosteroids) are administered as primary therapy or to 
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permit graft tolerance (e.g. BM transplantation) but, in doing so, predispose the patient to 
infection. Anti-resorptives (e.g., bisphosphonates) have been shown to mitigate bone loss but 
are limited by inconsistent outcomes and negative side effects of short and long-term use, 
including osteonecrosis of the jaw and atypical fractures (33, 34).
In contrast to pharmacological-centric therapies, exercise is recognized as a non-drug 
deterrent of cancer, as well as a means to protect musculoskeletal health. Indeed, the 
attributes of physical activity have helped promote it as a foundation of any therapeutic plan 
(35–37). Paradoxically, for cancer patients already at risk for developing a fracture, even a 
moderate exercise regimen may precipitate the fractures that the treatment is prescribed to 
prevent. In an effort to incorporate non-drug strategies for those with a compromised 
musculoskeletal system, low-intensity vibration (LIV), a mechanical signal which mimics 
the dynamics of muscle contraction, has been shown to protect bone quality in a murine 
model susceptible to ovarian cancer (38). LIV’s effects have been observed in both in vitro 
and in vivo systems to promote highly-ordered tissue synthesis (39, 40), upregulate 
musculoskeletal quality (41–43), and enhance cytoskeletal architecture of precursor bone 
cells (44, 45), while preserving the viability of the BM niche (46–48). Previous work by our 
group and others have demonstrated LIV as having an anabolic effect that encourages, at the 
level of the MSC, lineage differentiation towards osteogenesis and away from an adipogenic 
phenotype (49, 50). Contrarily, in the absence of mechanical loading, administration of LIV 
has been shown to reduce osteoclast activity across the endosteal surface (51) On the order 
of the cell, LIV has been shown to both decrease resorptive activity while also enhancing 
cytoskeletal proteins (52). To determine whether LIV is an effective agent against bone loss 
associated with myeloma, a xenograft mouse model was developed and, with the disease 
allowed to progress for 8w, quantified to what degree osteolysis and tumor progression had 
been influenced.
2. Materials and Methods
2.1. Human Myeloma Cell Culture and Expansion
A cryogenically preserved human-myeloma cell line (U266β1; ATCC; Manassas, VA, USA), 
was thawed and cultured using aseptic techniques. Centrifugation was used to separate (4°C, 
125g, 6min) cell pellets from media containing dimethyl-sulfoxide (DMSO). Pellets were 
resuspended in a 25cm2 tissue culture flask with 10mL of growth media and incubated 
horizontally (37°C in 5% CO2 atmosphere). Cell viability was quantified every 3d using an 
automated cytometer (Countess; Invitrogen; Rockville, MD, USA) until confluence (~97% 
viability), at which time the cell suspension was centrifuged (24°C, 2 200rpm, 5min), 
resuspended, and split 1:3 into 75cm2 tissue culture flasks. According to manufacturer’s 
recommendations, subcultures were maintained at a density of 3.5×105–1×106 cells/mL 
until day of injection.
2.2. Murine Model
All mice were individually housed. Power calculations were performed to account for effect-
size (0.25) and for statistical power of at least 0.8. Age-Matched Control (AC; n=8), 
Myeloma-Injected (MM; n=12), and Myeloma-Injected treated with Low Intensity Vibration 
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(LIV; n=13) groups were distributed using a Matlab (The MathWorks, Inc.; Natick, MA, 
USA) algorithm that randomizes samples by weight matching. U266β1 cells were inoculated 
intravenously via tail vein into 7w-old, male immunodeficient NSG mice (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ; The Jackson Laboratory; Bar Harbor, ME, USA) (53). 25 NSG 
mice (MM and LIV) were injected with 0.3cc of 2×106 U266β1 via a sterile saline vehicle, 
while AC mice were injected with 0.3cc of sterile saline as control. Of the 25 U266β1-
injected mice, 13 were subjected to 8w of LIV, while the remaining 12 received sham-LIV 
(MM). Criteria were established to exclude tissue samples from analyses if the associated 
mouse died prematurely, else all samples were utilized. Mice were maintained in accordance 
with the Institutional Animal Care and Use Committee guidelines at Stony Brook University 
and the NIH Guide for the Care and Use of Laboratory Animals.
2.3. Daily Mechanical Loading Protocol
Loading regimens commenced 4hrs post-inoculation providing a rest period in order to 
mitigate stress induced from handling. Mice assigned to the mechanical loading regimen 
were subject to LIV (0.3g ± 0.025 @ 90Hz, where 1g = Earth’s gravitational field or 
9.8m/s2) (38, 47, 51), for 15min/d, 5d/w, while AC and MM groups underwent identical 
handling and loading protocols as LIV mice but without activation of the platform. The daily 
loading regimen consisted of placing mice into individual 12cm×12cm containers on a fixed, 
vertically-oscillating platform (Marodyne Medical; Tampa, FL, USA) to administer the LIV 
signal. Displacements required to produce accelerations at 90Hz are well below 100μm and 
are barely perceptible to human touch. The lead investigator was not blinded to the 
experimental groups during the delivery of LIV.
2.4. Tissue Harvest and Preservation
At the end of the 8w protocol, each mouse was anesthetized using isoflurane inhalation and 
whole blood collected via cardiac puncture. Blood was then heparinized and aliquoted 
(100μl) for FACS analysis after erythrocyte lysis (1× Pharmalyse; BD Biosciences, San Jose, 
CA, USA). Euthanasia was achieved by cervical dislocation. Left femora were briefly 
preserved on ice, and BM was extracted and isolated using Dulbecco’s modified Eagle’s 
supplemented medium (DMEM; GIBCO; Grand Island, NY, USA) containing 2% FBS, 
10mM HEPES Buffer, and 1% penicillin–streptomycin (DMEM+). Tissues for histological 
processing, including right femora and tibia, were fixed in 10% neutral buffered formalin, 
replaced at 48h with 70% ethanol, and subsequently sectioned. Bone specimens were 
decalcified (DECAL; Decal; Suffern, NY, USA) and 5μm paraffin-embedded sagittal cross-
sections were stained with hematoxylin and eosin (H&E). Prevalence of MM and evaluation 
of tumor burden were determined via histologic examination, performed by a 
histopathologist (KRS) who was blinded to the status of any mouse’s experimental regimen.
2.5. Flow Cytometric Analyses of Femoral Bone Marrow
Flow cytometric analyses (FACSAria Cytometer; BD Pharmingen; San Diego, CA, USA) 
utilized specific markers to isolate and quantify cells of both the lymphoid and myeloid 
lineages. As reported, the FACS data represents the average of all cell populations quantified 
separately for each mouse across each group. Since the immune deficient mice do not have 
viable, native plasma cells, FACS analysis was performed using an antibody for the surface 
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marker CD138 (syndecan-1), a cell-membrane protein specific to all plasma cells, to 
determine engraftment efficacy of the myeloma cells that had been injected (54). Peripheral 
blood was tested for the presence of CD138+ cells. Whole marrow from femora were 
individually isolated and homogenized in 3mL of DMEM+ in order to maximize cell 
viability before tissue processing. Subsequent steps consisted of macroparticle filtration, 
erythrocyte lysis, and washing with 1mL of DPBS and centrifugation (4°C, 2000rpm, 
10min). 2×106 marrow cells from each sample were quantified from each mouse using an 
automated cell counter (Scepter; Millipore; Billerica, MA, USA), fixed with 1% NBF in 
Hank’s Buffered Salt Solution, and stained for specific hematopoietic surface markers. 
Human myeloma cells (CD138+: Catalog #561703, BD Pharmingen), mature macrophages 
(CD11c+/F4-80+: #557401, BD Pharmingen & Catalog #45-4801-82; EBioscience.com; San 
Diego, CA, USA), and a marker for precursor natural killer (NK) cells (NK1.1+: Catalog 
#553164, BD Pharmingen) were quantified based on fluorescent antibody-tagging.
2.6. Histological Evaluation of Tumor Burden
Histologic sections were used to estimate the tumor area fraction (percent of native marrow 
replaced with myeloma cells). Images were taken of longitudinal, paraffin-embedded H&E-
stained sections of bone (20×) using digital histological software (Aperio ImageScope; Leica 
Biosystems; Buffalo Grove, IL). Marrow area (MA), tumor area (TA), and necrotic tumor 
area (NT) were individually demarcated using image-processing software (ImageJ; National 
Institutes of Health; Bethesda, MD, USA). MA was defined as the non-cancellous tissue 
bounded by the endosteal surface of the cortex, from the length of the diaphyseal midshaft to 
the distal end of the femur. TA was outlined within the MA and quantified. Additionally, 
regions of NT were outlined and quantified from within the TA. Immunohistochemistry on 
formalin-fixed paraffin embedded bone sections was performed to validate the presence of 
tumor using an antibody for surface-bound CD138 at a 1:25 dilution (PA5-32305; Thermo 
Scientific, Rockford, IL). Annexin V (ab14196; Abcam Inc.; Cambridge, MA) was used at a 
dilution of 1:500 as a marker for validation of necrotic tumor in the tibial bone marrow.
2.7. High-Resolution Micro-Computed Tomography and Analyses of Cortical and 
Trabecular Bone Morphology
Quantity and quality of bone across the distal femoral, proximal tibial metaphysis, and L5 
vertebrae were measured ex vivo using X-ray micro-computed tomography (μCT40; Scanco 
Medical; Wayne, PA, USA). X-ray source voltage was set to 55kVp, current set to 145μA, 
integration time was 300ms, and voxel size was 10μm. Parameters measured were as 
follows: trabecular bone volume fraction (Tb.BV/TV), cortical bone volume fraction 
(Ct.BV/TV), and the number of transcortical perforations. Starting 700μm distal to the 
epiphyseal growth plate in the tibia and 700μm proximal to the growth plate of the femur, 1 
000μm of metaphyseal bone was evaluated. A 500μm uniform core of trabecular bone, 
taking care not to include primary spongiosa, was evaluated within the vertebral body of the 
L5 vertebrae. Thresholds for each slice were set exclusively to separate cortical and 
trabecular bone using an automated script (55). Reconstructed solid 3D images were then 
used to quantify bone microarchitecture and the number of perforations that extended from 
the periosteum to the endosteal surface. Digitally slicing the 3D reconstructed image along 
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the sagittal and transverse axes revealed perforations, and these were included if they 
breached the periosteal surface.
2.8. Static Histomorphometry
2D-point counting stereology was used to quantify the bone resorbing and bone forming 
surfaces in trabecular bone of the distal femur. Briefly, a 36-point Merz Grid was 
superimposed on the region-of-interest at 200× magnification (BV/TV was quantified at 
100× magnification) and grid intersections with either eroded surfaces per trabecular surface 
(ES/TS: presence of multinucleated osteoclasts and/or clear evidence of trabecular 
resorption pits) or forming surface per trabecular surface (OB/TS: cuboidal, basophilic cells 
on trabecular bone surfaces) were determined as a percentage of the total intersections with 
trabecular bone surface. Resorption surface was defined as trabecular surfaces undergoing 
resorption by multinucleated osteoclasts and/or crenated trabecular surfaces with clear 
evidence of osteoclast resorption (i.e. resorption lacunae/scalloped surfaces with no evidence 
of osteoblast formation). All readings were performed blind to the experimental history of 
the specimen. These analyses were performed by a histomorphometrist (SDB) who was 
blinded to the status of any mouse’s experimental regimen.
2.9. Osteoclast Activity (Serum-TRACP5b)
To provide a systemic index of osteolysis, serum was isolated from peripheral blood through 
centrifugation (4°C, 2 500rpm, 10min), aliquoted, and stored at −80°C. Samples were 
thawed to room temperature before performing an immunoassay to quantify osteoclast 
(OC)-secreted tartrate-resistant acid phosphatase (TRACP5b) (MouseTRAP; 
Immunodiagnostics; Scottsdale, AZ, USA). The assay was performed according to 
manufacturer’s instructions. Mean absorbance was fit to a standard curve to obtain the 
sample concentration.
2.10. Statistical Analyses
Group-wise comparisons were made between AC, MM, and LIV groups. All graphical data 
is presented as dot plots with bars representing means ± standard deviation. Significance 
(α<0.05) between MM and LIV groups as a function of the presence and degree of 
pathology was determined using Student’s two-tailed t-test. The Shapiro-Wilk test was used 
to confirm the normality of the FACS and micro-CT sample distribution. One-way ANOVA 
was performed for micro-CT, FACS, and TRACP5b analyses between AC, MM, and LIV, 
followed by Tukey’s post-hoc test. Pearson’s correlations were made using a 95% 
confidence interval (p<0.05). Variances in bone quantity and marrow between non-injected 
and injected animals were estimated to be significantly different as a function of pathology.
3. Results
3.1. Animal Habitus
None of the mice from any of the experimental groups were lost prematurely over the 8w 
experimental period. No significant differences were measured between groups in mouse 
weights or food consumption (Supplemental Fig. 1).
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3.2. Expansion of Myeloma Across the Marrow Space was Suppressed by Mechanical 
Signals
The NSG mouse model is genetically prohibited from developing mature lymphocytes, 
including terminally-differentiated B cells (i.e. plasma cells) and mature NK cells; therefore, 
detection of viable plasma cells in the marrow is indicative of successful engraftment (53). 
As compared to AC marrow, which maintained a healthy, red phenotype, evaluation of the 
marrow from MM and LIV indicated regions ≥ 1mm where normal marrow had been 
displaced by confluent sheets of plasma cells (Fig. 1). Histologic evaluation in both MM and 
LIV mice showed that resulting displacement of resident marrow constituents was consistent 
with profound anemia, leukopenia, and neutropenia. Extending further into the host marrow, 
plasma cells became visibly diffuse amongst the reticulocyte, granulocyte, and erythrocyte 
populations.
Tumor burden infiltrated 72% ± 15% of the femoral marrow space in MM, as compared to a 
50% ± 26% invasion in LIV (Fig. 1), indicating a 31% (p<0.01) suppression by the 
mechanical signals. 100% of MM (12/12) and LIV (13/13) mice contained myeloma in the 
tibia, with the tumor crowding into 63% and 62% of the marrow space for MM and LIV, 
respectively. Necrotic tumor, representing a later stage of the disease, was evident in 42% 
(n=5) MM mice tibiae, as compared to 8% (n=1) of LIV tibiae with evidence of necrosis 
(Fig. 2). Sites of necrosis across the bone marrow were observed in the mid-diaphysis and 
extending beyond the growth plate into the epiphysis using an antibody for Annexin V. 
Within the MM group, tumor necrosis accounted for 50% of the tumor quantified in the 
marrow. Necrotic tumor occupied 40% of the tibial marrow space of MM, as compared to 
only 8% in LIV. No necrosis was observed in the femur of either group.
Osteolysis was visible at sites adjacent to myeloma tumors and was evident across the 
endosteal surface of both MM and LIV, including deep cortical resorption pits that breached 
the cortex from the marrow space to the periosteal surface. Extensive resorption pits 
(Howship’s lacunae) were evident along the endosteal surface of both MM and LIV, adjacent 
to the infiltrating tumor, which often coincided with the presence of disorganized, woven 
bone within the cortical shell.
3.3. LIV Reduced Myeloma Cell Populations within the Marrow Space but Did Not Disrupt 
Immune Cell Reactivity
FACS quantification of overall marrow cellularity yielded a uniform measurement across all 
groups (NSD between groups) (Fig. 3). Homing of the injected cells was observed in the 
marrow of all 25 of the U266β1-injected mice. As measured in the marrow from the left 
femur, CD138+ cells were detected as 15× higher in MM as compared to AC, with LIV 
reducing this by 40% (9× increase as compared to AC). Precursor natural killer cells 
(NK1.1+) were 13× (p<0.003) greater in both MM and LIV as compared to AC, whereas 
differences between MM and LIV were negligible. Total mature macrophages (CD11c+/
F4-80+) were 61% (p<0.05) greater in MM as compared to AC, with LIV reducing this by 
26% (a 45% increase compared to AC).
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3.4. Bone Quality Disrupted by MM Disrupted by MM was Protected by LIV
Femora—Micro-CT analyses of the distal femur revealed the trabecular bone volume 
fraction (Tb.BV/TV) in MM was reduced by 86% (p<0.001) as compared to AC, whereas 
LIV was only 21% (p<0.01) lower than AC, reflecting a 76% (p<0.01) improvement as 
compared to MM (Fig. 4). Cortical bone volume fraction (Ct.BV/TV) of the distal femur of 
MM was 21% (p<0.01) lower than AC, as compared to a 15% (NSD) lower value in LIV 
compared to AC, reflecting a 30% (p<0.01) improvement of LIV compared to MM.
Tibiae—Micro-CT analyses of the proximal tibiae demonstrated a 70% (p<0.001) decrease 
in trabecular bone volume fraction (Tb.BV/TV) in MM versus AC. Tb.BV/TV in LIV mice 
was 62% (NSD) lower than AC, but the 27% higher amount was also not significantly 
different than MM. (Fig. 4).Tissue mineral density in the proximal tibia was 39% (p<0.001) 
lower in MM as compared to AC, but fell only 27% (p<0.002) in LIV.
Vertebrae—Tb.BV/TV in L5 vertebrae of MM mice were 35% (p<0.001) lower than in 
AC, while LIV mice had 17% (NSD) less bone than AC, a measure that was 27% (p<0.05) 
greater as compared to MM (Fig. 5). Trabecular connectivity density (Conn. Dens.) in MM 
was 36% (p<0.05) lower than in AC, whereas in LIV only 6% (NSD) reduction was 
measured in AC, or 47% (p<0.05) greater than those of MM. The number of trabeculae 
(Tb.N.) in the L5 of MM had decreased by 16% (p<0.05) versus AC while decreasing by 
just 5% (NSD) in LIV in comparison to AC, a mark that 13% (NSD) greater than MM. As a 
measure of bone quality, the structure model index (SMI) of MM mice was 37% (p<0.01) 
greater than in AC, and while the trabeculae of LIV was 31% (p<0.05) greater than in AC 
this measure was reduced by just 5% (NSD) in LIV versus MM.
Cortical Perforations of the Femur—Transcortical perforations in AC femora were 
9.6× greater in MM as compared to AC, contrasted with a 4× increase in LIV (Fig. 6). This 
reflects a 57% (p<0.002) reduction of osteolytic perforations of the cortex in those mice 
subject to LIV. The number of transcortical perforations positively correlated to the percent 
area of tumor tissue in the femur (R2=0.284; p<0.0005) (Fig. 6).
3.5. Elevated Osteoclast Activity with Myeloma was Suppressed by LIV
Based on histomorphometric analyses at the distal femur, no primary spongiosa were 
observed in MM, yet they were partially protected by LIV. (Fig. 7) Growth plates appeared 
disrupted in MM, and in several cases islands of mineralized cartilage were evident in bone 
marrow. The Tb.BV/TV measured in MM was 75% (p<0.001) lower than in AC, while LIV 
was 36% (p<0.05) below AC, resulting in 60% (p<0.01) greater BV/TV than in MM, 
reinforcing the results derived from CT (above). Eroded surface per trabecular surface 
(ES/TS) of MM was 70% (p<0.05) greater than AC, while LIV was 29% (NSD) below AC, 
and thus 58% (p<0.0001) below MM. Osteoblast number per trabecular surface (OBl/TS) 
was 14% (NSD) lower in MM as compared to AC, whereas LIV was 7% (NSD) greater than 
AC and 24% (NSD) greater than MM.
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A systemic measure of osteoclast activity, serum-TRACP5b, rose by 61% (p<0.001) in MM 
as compared to AC. However, these levels had increased by only 33% (p<0.05) in LIV as 
compared to AC, yielding a 45% (p=0.06) reduction from that measured in MM (Fig. 8).
4. Discussion
4.1
The destruction of bone marrow by myeloma plasma cells facilitates cortical and trabecular 
resorption and transcortical perforations (11, 56), concurrently elevating fracture risk and 
perturbing the immune system. And while exercise is recognized as an effective non-drug 
means of suppressing both cancer and osteoporosis, strenuous activity for this patient 
population may induce the very fracture it is prescribed to prevent. Serving as a surrogate for 
exercise, this study was designed to evaluate if low intensity vibrations, a physical signal 
demonstrated to stimulate osteoblastogenesis and reduce adipogenesis (43, 47), as well as 
suppress osteoclast activity (57), could slow the precipitous drop in bone quality 
accompanying myeloma infiltration of bone without serving as an anabolic signal to the 
tumor. The data suggest these extremely low magnitude mechanical signals helped to protect 
the bone phenotype, with some evidence that the progression of the tumor itself was 
suppressed.
Tumor burden was significantly lower in the femur of LIV mice than in engrafted mice that 
did not receive the mechanical intervention. In an effort to differentiate the degree of cancer 
progression between groups, the histological grade of the BM tumor was noted as either 
viable or necrotic tumor, the latter accounting for 42% (n=5 of 12) of the observations in 
MM tibiae but just 8% of the engrafted animals treated with LIV (n=1 of 13). This late-stage 
pathology is consistent with a more advanced grade of symptomatic myeloma and reflected 
by the fact that regions of viable tumor were predominantly void of the cellular composition 
of healthy marrow (58, 59), where necrotic tumor occupied 40% of the tibial marrow space 
of MM, as compared to only 8% in LIV. No necrosis was observed in the femur of either 
group. Given that the marrow volume of the femur is approximately twice that of the tibia, 
this suggests that an early stage in the pathogenesis of the disease may be to crowd out the 
healthy marrow, and once that occurs, marrow necrosis begins as aggravated by the absence 
of a viable marrow to support it. Alternatively, it is entirely possible that spatially distinct 
marrow populations may account for the differential progression of the tumor in the tibia vs. 
the femur, as well as the distinct responses of these bones to the mechanical intervention 
(60). Extrapolating to the clinic, it suggests that any intervention that slows the crowding of 
the marrow by the tumor would, naturally, slow the inevitable advance of necrosis that 
follows.
Utilizing mechanical signals to mitigate skeletal decline as a comorbidity of cancer – and its 
treatments – while maintaining quality of life shows some potential as a future clinical 
strategy, perhaps in tandem with other interventions. The reduced tumor burden measured in 
the marrow of the femur of LIV mice suggests that preservation of the marrow 
microenvironment in turn may help protect the bone organ. This conclusion is supported by 
the correlation between tumor area and quality of bone (Fig. 6). Further, the marked 
reduction in transcortical perforations and resorptive surface measured in LIV mice (Fig. 7), 
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reinforces that myeloma is permissive to osteolysis but that mechanical signals can slow this 
pernicious decline in bone structure.
Through signaling pathways are not yet understood, it is possible that mechanical signals not 
only slow the disruption of the marrow space, but preserve key aspects of the balance of 
bone remodeling. While the disease state clearly elevates resorptive activity, the apparent 
absence of any rise in formative activity fails to keep pace with the loss of bone, suggesting 
a consequence of the disease is the ‘uncoupling’ of bone remodeling. The ability of LIV to 
suppress the elevation of osteoclast activity is supported by the demonstrated ability of these 
mechanical signals to decrease osteoclast recruitment in hindlimb unloaded animals (51), as 
well as preserve bone formation activity under systemic suppression of activity disabling 
conditions such as cerebral palsy (46, 48). It is also possible that through the mechanical 
biasing of mesenchymal and hematopoietic stem cell fate towards specific endpoints (e.g., 
osteoblastogenesis and lymphopoeisis, respectively), that these physical signals slow the 
engraftment of myeloma cells and the conscription of osteoclasts, both of which are critical 
to advancement of the disease and the skeletal complications that follow (61).
Serum TRACP5b and static histomorphometry data reinforce a pronounced catabolic 
consequence of myeloma on the skeleton, and support the anti-resorptive endpoints on bone 
morphology as measured with CT. Therefore, it is reasonable to suggest that LIV may 
provide a means of introducing protective mechanical signals to normalize the bone cellular 
process in the face of disease-specific perturbations of the balance of remodeling. That LIV 
failed to protect bone quality in the tibia of myeloma mice as well as that measured in the 
femur can be interpreted several ways. One possibility is that the volume of marrow in the 
tibial compartment is approximately half that of the femur, and that mechanical signals 
simply could not outpace the progression of the disease. That said, it is interesting that the 
level of actual necrosis in the tibia of myeloma mice that served as sham control was higher 
than that measured in LIV, suggesting at least some capacity to deter the late stages of the 
pathology was evident. Alternatively, or in conjunction, there is evidence of spatial 
differences of marrow, not only within a given bone (62), but between bones (60), as well as 
the capacity of mechanical signals to influence bone morphology at these different sites. 
With evidence of the consequences of the disease evident in the axial skeleton, with some 
salutary benefit of LIV to protect skeletal components remote from the site of vibration, 
suggests circulatory factors may also be at play.
This study has several limitations. Methods of ensuring adequate engraftment may have 
introduced a disproportionate burden of malignant cells to the marrow than that which 
occurs during natural progression of myeloma development (63–65). Immunodeficient 
models introduce key mutational defects in immune surveillance (66, 67) and offer 
compromised hematopoiesis, increasing consistency in human cell line engraftments (68). 
Specifically, severe combined immune deficient (SCID) mice are engineered with impaired 
T and B lymphocyte development and function (66, 69, 70). In this vein, it is important to 
highlight that, while cells of the innate immune system (i.e. macrophages, granulocytes) 
were genetically intact to combat the tumor burden, elements of adaptive immunity were not 
present to enhance natural defenses against the cancer progression (71–74), as was reflected 
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by the significant increases in precursor-NK cell (NK1.1+) and mature macrophage 
(CD11c+/F4-80+) activity quantified by FACS in both MM and LIV (Fig. 3).
That only the hindlimbs and axial skeleton were evaluated precludes an estimate of overall 
impact on the skeleton and other organs, such as the spleen, which is a site associated with B 
cell maturity and plasma cell infiltration. With marked increase in TRACP5b measured in 
the myeloma mice invariably points to a systemic elevation of osteoclast activity as 
compared to AC counterparts, these levels were significantly reduced by the introduction of 
LIV. This view is supported, at least in part, by the marked reduction in bone quality in the 
femur and spine, and the capacity of LIV to protect these regions, as well as the 
histomorphometric evidence of reduced osteoclast activity in the mechanically stimulated 
mice.
Recent efforts have been made to develop immunocompetent models of myeloma, thereby 
retaining the animals’ immunity (75). Nevertheless, many characteristics of this model, 
specifically compromised bone quality, damaged cortex, and marrow destruction, mirror the 
phenotypic outcomes of the native disease. Additionally, the advanced state of tumor burden 
when considered in light of a relatively short study duration was quite severe. These findings 
are byproducts of U266β1 alone and may vary across other myeloma cell lines, specifically 
those of a primary myeloma plasma cell.
And, of course, only one mechanical regimen was considered. It is entirely possible that 
other mechanical regimens, including exercise, could slow the progress of the disease, or 
that the introduction of refractory periods between LIV and/or exercise administration would 
augment the potential of mechanical signals to slow the pathology (76). It is encouraging, 
however, that mechanical signals, extremely low in intensity and brief in duration, could 
represent a salutary influence on skeletal quality, and may someday help curb the 
consequences of the disease in the human.
Perhaps the greatest limitation of the study is the extrapolation to the human condition. It 
was encouraging that a non-drug approach effectively slowed destruction of the bone 
phenotype without exacerbating the disease itself – and perhaps even serving to decelerate 
the rapid progression observed in this model. It cannot be emphasized strongly enough that 
this is a mouse model of a grave human disease, and over-interpretation of these data in that 
regard must be avoided. Nevertheless, a recent study which explores the use of LIV on 
children cancer survivors demonstrates that this mechanical intervention can be safely 
applied to the human to build bone density without compromising health (77). As 
combination therapies point towards improved outcomes, perhaps an effective clinical 
strategy may incorporate mechanical signals in the form of exercise or other physical 
modalities alongside chemotherapy or irradiation, to mitigate myeloma-associated osteolysis 
while combating tumor progression.
Morphological, histological and biochemical endpoints emphasize the destructive capacity 
of myeloma cells as they propagate, with profound consequences on bone quality and 
marrow viability. This murine model bearing myeloma resulted in aggressive osteolysis and 
rapid destruction of healthy marrow. Low intensity vibration, serving as a surrogate for 
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exercise, slowed the degradation of the bone and marrow phenotype and suppressed the 
invasion of the tumor.
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Highlights
• Bone and marrow quality were compromised in a murine model of 
multiple myeloma (MM).
• Reduced bone quality and increased cortical perforations correlated to 
increased tumor burden.
• Low intensity vibration (LIV) suppressed appendicular and axial 
skeletal damage provoked by MM.
• LIV mitigated tumor burden, including a reduction in marrow necrosis.
• TRACP5b and histologic evidence of resorptive surface were lower in 
LIV, indicating suppression of osteoclastic activity in MM subject to 
mechanical signals.
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Figure 1. 
(Top) Longitudinal 5μm histological sections (0.7×) of H&E-stained femurs across the 
medullary cavity. AC marrow contained healthy hematopoietic cells throughout the cavity, 
while cortical bone was unperturbed across the length of the shaft. In MM the confluent 
tumor burden was evident in the marrow space (yellow-dashed line). A continuous sheet of 
plasma cells reach to and encroach the growth plate and are found within resorption pits that 
perforate the cortical shell. Trabecular bone was visibly reduced in MM. Tumor burden was 
evident in LIV but to a lesser extent than that of MM. Relative to AC, cortical thinning was 
evident in both MM and LIV, but the resorption was not as pronounced in LIV. (Bottom 
Left) H&E histological section (40×; 5μm) of a cortical resorption pit at the distal femur. 
Osteolysis was perpetuated by an influx of A.) myeloma cells that have infiltrated the 
marrow, and B.) osteoclasts, which have subsequently propagated to the bone lining. At the 
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interface of bone and marrow, the cortical resorption pit demonstrates the relationship 
between myeloma cells and their capacity to initiate osteoclast-mediated resorption. These 
sites are surrounded by disorganized, woven bone on the cortex and at the growth plate. 
(Bottom Middle) Antibody staining for CD138+ cells demonstrates the delineation of A.) 
healthy marrow and B.) tumor. (Bottom Right) Quantification of viable tumor throughout 
the femoral BM indicated a 31% reduction in LIV as compared to MM.
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Figure 2. 
Histological quantification of viable tumor was performed across the tibial marrow space 
resulting in 64% occupation of MM marrow, identical to the 63% (NSD) in the marrow of 
LIV. A.) In contrast to the femur, however, necrotic tumor was observed in 42% of the tibiae 
of MM group (n=5), as compared to 8% of LIV (n=1), indicating a more advanced stage of 
disease progression. B.) Note the correlation of osteolytic lesions and resorption to the 
degree of myeloma cell encroachment in the marrow. Tumor necrosis (Annexin V+) was 
evident in the C.) tibial metaphysis and D.) across the growth plate into the epiphysis.
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Figure 3. 
FACS analysis of hematopoietic components of femoral BM. A.) As compared to AC, FACS 
of BM from the left femora of LIV showed a 40% decrease of CD138+ cells as compared to 
MM (p=0.08). B.) Total mature macrophages were 61% (p<0.05) greater in MM as 
compared to AC, while there were 26% (NSD) fewer in LIV as compared to MM. C.) 
Progenitor-NK cells (NK1.1+) in MM and LIV were 1332% (p<0.003) and 1310% 
(p<0.003) greater, respectively, than in AC. These data indicate that although the animal is 
immunocompromised, certain elements of the immune system are still responsive to the 
disease, here indicated by the level of CD138+ cells in the marrow.
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Figure 4. 
Micro-CT analysis of segmented bone parameters in the (Top) femur and (Bottom) tibia 
were used to measure differences in bone quantity and quality. Quantification of the distal 
femora revealed an 85% (p<0.04) lower trabecular bone volume fraction (Tb.BV/TV) in 
MM as compared to AC. In contrast, LIV was only 21% lower than AC, reflecting a 75% 
‘benefit’ of mechanical stimulation over MM alone. Cortical BV/TV (Ct.BV/TV) of the 
femoral metaphysis was 21% (p<0.03) lower in MM as compared to AC, while LIV was 
15% lower, reflecting a 30% protective benefit of LIV. Tibial Tb.BV/TV across the proximal 
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tibia was 70% (p<0.001) lower in MM as compared to AC, while decreasing by only 62% 
(NSD) in LIV from AC, a mark 27% greater than in the MM comparison. Tissue mineral 
density had decreased by 39% (p<0.001) in MM as compared to AC decreasing by just 27% 
(p<0.002) in the tibiae of LIV mice.
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Figure 5. 
Representative micro-CT (voxel resolution = 10μm) analysis of the L5 region of the axial 
skeleton. Trabecular bone was digitally isolated from the cortical shell of the vertebral body 
in order to quantify bone quantity and quality. BV/TV in MM mice were 35% (p<0.001) 
lower than in AC, LIV mice had 17% (NSD) less bone than AC, a measure that was 27% 
(p<0.05) greater as compared to MM. Trabecular connectivity density in MM mice was 36% 
(p<0.05) lower than in AC, whereas LIV mice were only 6% (NSD) less than in AC, a 
measure that was 47% (p<0.05) greater than those of MM. The number of trabeculae in the 
L5 of MM had decreased by 16% (p<0.05) versus AC while decreasing by just 5% (NSD) in 
LIV in comparison to AC, a mark that was 13% (NSD) greater than MM. The structure 
model index (SMI) indicated that trabecular bone was more rod-like in MM and LIV than 
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AC, as this index was 37% (p<0.01) greater in MM than AC, but just 31% (p<0.05) greater 
in LIV than AC.
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Figure 6. 
Representative micro-CT (voxel resolution = 10μm) whole bone and transverse cross-
sectional reconstructions of distal metaphyseal region of the femur. (Top) AC bones have a 
uniform, smooth periosteal surface and robust trabecular formation. Severe osteolysis and 
extensive porosities were observed in MM femora, demonstrating the pathology directly 
associated with U266β1 engraftment into the medullary canal. LIV bones, while not fully 
preserved, showed fewer perforations and a greater degree of trabecular conductivity. 
(Bottom) Transcortical perforations in MM were 9× (p<0.0001) greater than AC, a 
deterioration which fell 57% (p<0.003) in LIV. A correlation between degree of osteolysis 
and tumor burden (R2=0.284.; p<0005) suggests a strong interaction of the two 
consequences of the disease.
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Figure 7. 
Static histomorphometry was performed on histological sections of distal femora to discern 
the degree to which LIV effected resorption or formation. (Top Left) BV/TV was 
significantly reduced (p<0.0001) in MM from AC, a mark which improved by 60% 
(p<0.001) in the LIV-treated animals, all of which reflected data quantified via micro-CT 
analyses. (Top Right) As a measure of degree of bone resorption, resorptive surface per total 
surface was 70% (p<0.05) and 29% (NSD) greater in MM and LIV, respectively, as 
compared to AC. Introduction of LIV appears to have mitigated the degree of resorption by 
58% (p<0.0001) than in myeloma animals denied LIV treatment. However, as an indication 
of bone formation, (Bottom) osteoblast counts in the same region (OBl/TS) were 14% 
(NSD) lower in MM as compared to AC mice. LIV appears to encourage a modest 24% 
(NSD) increase from MM-only mice. Overall, this indicates that a more anti-resorptive 
mechanism on trabecular surfaces was responsible for mitigating the osteolysis.
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Figure 8. 
Immunoassay performed to detect serum-bound tartrate-resistant acid phosphatase 
(TRACP5b) was isolated from peripheral blood. Significantly greater osteoclast activity was 
quantified in animals bearing myeloma (MM and LIV), versus those of the AC group. 
Serum-TRACP5b measured from MM was 61% (p<0.001) greater in the MM versus AC. 
Introduction of LIV reduced serum-quantified osteoclast activity to 33% (p<0.05) greater 
than AC but 45% (p<0.06) below detected levels in MM.
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